Back to top
more

DBV Technologies (DBVT)

(Delayed Data from NSDQ)

$0.69 USD

0.69
2,576

+0.01 (1.62%)

Updated Apr 24, 2024 03:57 PM ET

After-Market: $0.66 -0.03 (-4.49%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Down -25.23% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)

by Zacks Equity Research

DBV Technologies S.A. (DBVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

BeiGene, Ltd. (BGNE) Surges 12.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

DBV (DBVT) Up as FDA Lifts Partial Hold on Peanut Allergy Study

by Zacks Equity Research

The FDA lifts the partial clinical hold on DBV Technologies' (DVBT) phase III VITESSE study of a modified Viaskin Peanut patch in peanut-allergic children aged four to seven years. Stock rises.

Kymera Therapeutics, Inc. (KYMR) Moves 9.6% Higher: Will This Strength Last?

by Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

DBV Technologies' (DBVT) Peanut Allergy Study on Partial Hold

by Zacks Equity Research

DBV Technologies (DVBT) announces partial hold on phase III study of modified Viaskin Peanut 250 ??g patch, VITESSE, by the FDA. Stock declines.

Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how DBV Technologies S.A. (DBVT) and ProPhase Labs, Inc. (PRPH) have performed compared to their sector so far this year.

NGM Biopharmaceuticals (NGM) Soars 6.8%: Is Further Upside Left in the Stock?

by Zacks Equity Research

NGM Biopharmaceuticals (NGM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Is Axonics (AXNX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Axonics Modulation Technologies (AXNX) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.

Is Lantheus (LNTH) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Lantheus Holdings (LNTH) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.

Has DBV Technologies (DBVT) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how DBV Technologies S.A. (DBVT) and Chinook Therapeutics (KDNY) have performed compared to their sector so far this year.

Down 42.6% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)

by Zacks Equity Research

DBV Technologies S.A. (DBVT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 36.6% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)

by Zacks Equity Research

DBV Technologies S.A. (DBVT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

New Strong Sell Stocks for January 27th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

New Strong Sell Stocks for January 13th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Biotech Stock Roundup: MRNA & REGN Gain on Coronavirus Treatment Updates & More

by Zacks Equity Research

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

DBV Technologies is in Overbought Territory: What???s Next?

by Zacks Equity Research

DBV Technologies has moved higher as of late, but there could definitely be trouble on the horizon for this company.

DBV Technologies S.A. (DBVT) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

DBV Technologies S.A. (DBVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

DBV Technologies S.A. (DBVT) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in DBV Technologies S.A. (DBVT).

Implied Volatility Surging for DBV Technologies (DBVT) Stock Options

by Zacks Equity Research

DBV Technologies (DBVT) needs investors to pay close attention to the stock based on moves in the options market lately.

    DBV Technologies (DBVT) Worth a Look: Stock Up 5.7%

    by Zacks Equity Research

    DBV Technologies S.A. (DBVT) was a big mover last session, as the company saw its shares rise nearly 6% on the day.

      Is DBV Technologies (DBVT) Stock a Solid Choice Right Now?

      by Zacks Equity Research

      DBV Technologies (DBVT) in the Medical-Biomedical/Genetics space is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.